Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients with and without primary sclerosing cholangitis include the following:
Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Murashima N, Chayama K, Kumada Η (2000). «Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis». Cancer88 (11): 2471–7. doi:10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T. PMID10861422.
Mecklin J, Järvinen H, Virolainen M (1992). «The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma». Cancer69 (5): 1112–4. doi:10.1002/cncr.2820690508. PMID1310886.
Lee S, Kim M, Lee S, Jang S, Song M, Kim K, Kim H, Seo D, Song D, Yu E, Lee S, Min Y (2004). «Clinicopathologic review of 58 patients with biliary papillomatosis». Cancer100 (4): 783–93. doi:10.1002/cncr.20031. PMID14770435.
Donato F, Gelatti U, Tagger A, Favret M, Ribero M, Callea F, Martelli C, Savio A, Trevisi P, Nardi G (2001). «Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy». Cancer Causes Control12 (10): 959–64. doi:10.1023/A:1013747228572. PMID11808716.
Zhu A, Lauwers G, Tanabe K (2004). «Cholangiocarcinoma in association with Thorotrast exposure». J Hepatobiliary Pancreat Surg11 (6): 430–3. doi:10.1007/s00534-004-0924-5. PMID15619021.
Roskams T (2006). «Liver stem cells and their implication in hepatocellular and cholangiocarcinoma». Oncogene25 (27): 3818–22. doi:10.1038/sj.onc.1209558. PMID16799623.
Sirica A (2005). «Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy». Hepatology41 (1): 5–15. doi:10.1002/hep.20537. PMID15690474.
Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients with and without primary sclerosing cholangitis include the following:
Valls C, Gumà A, Puig I, Sanchez A, Andía E, Serrano T, Figueras J (2000). «Intrahepatic peripheral cholangiocarcinoma: CT evaluation». Abdom Imaging25 (5): 490–6. doi:10.1007/s002610000079. PMID10931983.
Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y (1999). «Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI». J Comput Assist Tomogr23 (5): 670–7. doi:10.1097/00004728-199909000-00004. PMID10524843.
Sugiyama M, Hagi H, Atomi Y, Saito M (1997). «Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of endoscopic ultrasonography». Abdom Imaging22 (4): 434–8. doi:10.1007/s002619900227. PMID9157867.
Szklaruk J, Tamm E, Charnsangavej C (2002). «Preoperative imaging of biliary tract cancers». Surg Oncol Clin N Am11 (4): 865–76. doi:10.1016/S1055-3207(02)00032-7. PMID12607576.
Länger F, von Wasielewski R, Kreipe HH (2006). «[The importance of immunohistochemistry for the diagnosis of cholangiocarcinomas]» (στα German). Pathologe27 (4): 244–50. doi:10.1007/s00292-006-0836-z. PMID16758167.
Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K (2000). «Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma». Int J Radiat Oncol Biol Phys46 (3): 581–7. doi:10.1016/S0360-3016(99)00472-1. PMID10701737.
Alden M, Mohiuddin M (1994). «The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer». Int J Radiat Oncol Biol Phys28 (4): 945–51. doi:10.1016/0360-3016(94)90115-5. PMID8138448.
Choi C, Choi I, Seo J, Kim B, Kim J, Kim C, Um S, Kim J, Kim Y (2000). «Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas». Am J Clin Oncol23 (4): 425–8. doi:10.1097/00000421-200008000-00023. PMID10955877.
Park J, Oh S, Kim S, Kwon H, Kim J, Jin-Kim H, Kim Y (2005). «Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study». Jpn J Clin Oncol35 (2): 68–73. doi:10.1093/jjco/hyi021. PMID15709089.
Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, Colucci G (2006). «Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)». Ann Oncol17 (Suppl 7): vii73–7. doi:10.1093/annonc/mdl956. PMID16760299.
Knox J, Hedley D, Oza A, Feld R, Siu L, Chen E, Nematollahi M, Pond G, Zhang J, Moore M (2005). «Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial». J Clin Oncol23 (10): 2332–8. doi:10.1200/JCO.2005.51.008. PMID15800324.
Philip P, Mahoney M, Allmer C, Thomas J, Pitot H, Kim G, Donehower R, Fitch T, Picus J, Erlichman C (2006). «Phase II study of erlotinib in patients with advanced biliary cancer». J Clin Oncol24 (19): 3069–74. doi:10.1200/JCO.2005.05.3579. PMID16809731.
Yamamoto M, Takasaki K, Yoshikawa T (1999). «Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma». Japanese Journal of Clinical Oncology29 (3): 147–150. doi:10.1093/jjco/29.3.147. PMID10225697.
Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas Η (2002). «Changing international trends in mortality rates for liver, biliary and pancreatic tumours». J Hepatol37 (6): 806–13. doi:10.1016/S0168-8278(02)00297-0. PMID12445422.
Multiple independent studies have documented a steady increase in the worldwide incidence of cholangiocarcinoma. Some relevant journal articles include:
Rajagopalan V, Daines W, Grossbard M, Kozuch P (2004). «Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1». Oncology (Williston Park)18 (7): 889–96. PMID15255172.
Nagorney D, Donohue J, Farnell M, Schleck C, Ilstrup D (1993). «Outcomes after curative resections of cholangiocarcinoma». Arch Surg128 (8): 871–7; discussion 877–9. PMID8393652.
Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Murashima N, Chayama K, Kumada Η (2000). «Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis». Cancer88 (11): 2471–7. doi:10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T. PMID10861422.
Lu H, Ye M, Thung S, Dash S, Gerber M (2000). «Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients». Chin Med J (Engl)113 (12): 1138–41. PMID11776153.
Mecklin J, Järvinen H, Virolainen M (1992). «The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma». Cancer69 (5): 1112–4. doi:10.1002/cncr.2820690508. PMID1310886.
Lee S, Kim M, Lee S, Jang S, Song M, Kim K, Kim H, Seo D, Song D, Yu E, Lee S, Min Y (2004). «Clinicopathologic review of 58 patients with biliary papillomatosis». Cancer100 (4): 783–93. doi:10.1002/cncr.20031. PMID14770435.
Donato F, Gelatti U, Tagger A, Favret M, Ribero M, Callea F, Martelli C, Savio A, Trevisi P, Nardi G (2001). «Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy». Cancer Causes Control12 (10): 959–64. doi:10.1023/A:1013747228572. PMID11808716.
Zhu A, Lauwers G, Tanabe K (2004). «Cholangiocarcinoma in association with Thorotrast exposure». J Hepatobiliary Pancreat Surg11 (6): 430–3. doi:10.1007/s00534-004-0924-5. PMID15619021.
Roskams T (2006). «Liver stem cells and their implication in hepatocellular and cholangiocarcinoma». Oncogene25 (27): 3818–22. doi:10.1038/sj.onc.1209558. PMID16799623.
Liu C, Wang J, Ou Q (2004). «Possible stem cell origin of human cholangiocarcinoma». World J Gastroenterol10 (22): 3374–6. PMID15484322.
Sirica A (2005). «Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy». Hepatology41 (1): 5–15. doi:10.1002/hep.20537. PMID15690474.
Holzinger F, Z'graggen K, Büchler M (1999). «Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma». Ann Oncol10 (Suppl 4): 122–6. PMID10436802.
Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients with and without primary sclerosing cholangitis include the following:
Sharma M, Ahuja V (1999). «Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician's perspective». Trop Gastroenterol20 (4): 167–9. PMID10769604.
Bloom C, Langer B, Wilson S (1999). «Role of US in the detection, characterization, and staging of cholangiocarcinoma». Radiographics19 (5): 1199–218. PMID10489176.
Valls C, Gumà A, Puig I, Sanchez A, Andía E, Serrano T, Figueras J (2000). «Intrahepatic peripheral cholangiocarcinoma: CT evaluation». Abdom Imaging25 (5): 490–6. doi:10.1007/s002610000079. PMID10931983.
Tillich M, Mischinger H, Preisegger K, Rabl H, Szolar D (1998). «Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma». AJR Am J Roentgenol171 (3): 651–8. PMID9725291.
Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y (1999). «Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI». J Comput Assist Tomogr23 (5): 670–7. doi:10.1097/00004728-199909000-00004. PMID10524843.
Sugiyama M, Hagi H, Atomi Y, Saito M (1997). «Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of endoscopic ultrasonography». Abdom Imaging22 (4): 434–8. doi:10.1007/s002619900227. PMID9157867.
Schwartz L, Coakley F, Sun Y, Blumgart L, Fong Y, Panicek D (1998). «Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography». AJR Am J Roentgenol170 (6): 1491–5. PMID9609160.
Freeman M, Sielaff T (2003). «A modern approach to malignant hilar biliary obstruction». Rev Gastroenterol Disord3 (4): 187–201. PMID14668691.
Szklaruk J, Tamm E, Charnsangavej C (2002). «Preoperative imaging of biliary tract cancers». Surg Oncol Clin N Am11 (4): 865–76. doi:10.1016/S1055-3207(02)00032-7. PMID12607576.
Länger F, von Wasielewski R, Kreipe HH (2006). «[The importance of immunohistochemistry for the diagnosis of cholangiocarcinomas]» (στα German). Pathologe27 (4): 244–50. doi:10.1007/s00292-006-0836-z. PMID16758167.
Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K (2000). «Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma». Int J Radiat Oncol Biol Phys46 (3): 581–7. doi:10.1016/S0360-3016(99)00472-1. PMID10701737.
Alden M, Mohiuddin M (1994). «The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer». Int J Radiat Oncol Biol Phys28 (4): 945–51. doi:10.1016/0360-3016(94)90115-5. PMID8138448.
González González D, Gouma D, Rauws E, van Gulik T, Bosma A, Koedooder C (1999). «Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma». Ann Oncol10 (Suppl 4): 215–20. PMID10436826.
Choi C, Choi I, Seo J, Kim B, Kim J, Kim C, Um S, Kim J, Kim Y (2000). «Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas». Am J Clin Oncol23 (4): 425–8. doi:10.1097/00000421-200008000-00023. PMID10955877.
Park J, Oh S, Kim S, Kwon H, Kim J, Jin-Kim H, Kim Y (2005). «Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study». Jpn J Clin Oncol35 (2): 68–73. doi:10.1093/jjco/hyi021. PMID15709089.
Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, Colucci G (2006). «Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)». Ann Oncol17 (Suppl 7): vii73–7. doi:10.1093/annonc/mdl956. PMID16760299.
Bhargava P, Jani C, Savarese D, O'Donnell J, Stuart K, Rocha Lima C (2003). «Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report». Oncology (Williston Park)17 (9 Suppl 8): 23–6. PMID14569844.
Knox J, Hedley D, Oza A, Feld R, Siu L, Chen E, Nematollahi M, Pond G, Zhang J, Moore M (2005). «Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial». J Clin Oncol23 (10): 2332–8. doi:10.1200/JCO.2005.51.008. PMID15800324.
Philip P, Mahoney M, Allmer C, Thomas J, Pitot H, Kim G, Donehower R, Fitch T, Picus J, Erlichman C (2006). «Phase II study of erlotinib in patients with advanced biliary cancer». J Clin Oncol24 (19): 3069–74. doi:10.1200/JCO.2005.05.3579. PMID16809731.
Yamamoto M, Takasaki K, Yoshikawa T (1999). «Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma». Japanese Journal of Clinical Oncology29 (3): 147–150. doi:10.1093/jjco/29.3.147. PMID10225697.
Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas Η (2002). «Changing international trends in mortality rates for liver, biliary and pancreatic tumours». J Hepatol37 (6): 806–13. doi:10.1016/S0168-8278(02)00297-0. PMID12445422.
Multiple independent studies have documented a steady increase in the worldwide incidence of cholangiocarcinoma. Some relevant journal articles include:
Multiple independent studies have documented a steady increase in the worldwide incidence of cholangiocarcinoma. Some relevant journal articles include: